ABSTRACT Motivation: The wide use of DNA microarrays for the investigation of the cell transcriptome triggered the invention of numerous methods for the processing of microarray data and lead to a growing number of microarray studies that examine the same biological conditions. However, comparisons made on the level of gene lists obtained by different statistical methods or from different datasets hardly converge. We aimed at examining such discrepancies on the level of apparently affected biologically related groups of genes, e.g. metabolic or signalling pathways. This can be achieved by group testing procedures, e.g. over-representation analysis, functional class scoring (FCS), or global tests. Results: Three public prostate cancer datasets obtained with the same microarray platform (HGU95A/HGU95Av2) were analyzed. Each dataset was subjected to normalization by either variance stabilizing normalization (vsn) or mixed model normalization (MMN). Then, statistical analysis of microarrays was applied to the vsnnormalized data and mixed model analysis to the data normalized by MMN. For multiple testing adjustment the false discovery rate was calculated and the threshold was set to 0.05. Gene lists from the same method applied to different datasets showed overlaps between 42 and 52%, while lists from different methods applied to the same dataset had between 63 and 85% of genes in common. A number of six gene lists obtained by the two statistical methods applied to the three datasets was then subjected to group testing by Fisher's exact test. Group testing by GSEA and global test was applied to the three datasets, as well. Fisher's exact test followed by global test showed more consistent results with respect to the concordance between analyses on gene lists obtained by different methods and different datasets than the GSEA. However, all group testing methods identified pathways that had already been described to be involved in the pathogenesis of prostate cancer. Moreover, pathways recurrently identified in these analyses are more likely to be reliable than those from a single analysis on a single dataset.
INTRODUCTION
DNA microarrays accelerated dramatically the gene expression profiling of cells, and became therefore an important tool in many biomedical applications. In cancer research, microarray experiments are frequently performed for tumour classification and identification of marker genes (van't Veer et al., 2002; Golub et al., 1999; Giltnane and Rimm, 2004 ). When results obtained by different microarray studies examining the same biological conditions, e.g. differential expression between tumour and normal samples, are compared, the lists of differentially expressed genes hardly overlap (Ein-Dor et al., 2005) . Moreover, numerous statistical methods that are being used for the processing of microarray data exist, and result in dissimilar lists of differentially expressed genes as well (Allison et al., 2006) .
A recent addition to the repertoire of analysis methods is group testing, i.e. testing whether predefined lists of genes that belong to, e.g. a metabolic pathway, the same cellular function or cellular component are significantly changed as a group in a microarray dataset (Curtis et al., 2005) . Three approaches for this task are: (1) an over-representation analysis (ORA), where the genes in the predefined lists are analyzed to see which categories are represented more than expected by chance (Draghici et al., 2003) ; (2) a functional class scoring (FCS; Pavlidis et al., 2004; Mootha et al., 2003) , where the genes are ranked based on the correlation between their expression and the given phenotype and (3) a global test looking for associations between gene expression in predefined gene sets and a target variable (Goeman et al., 2004) .
Until now, results coming from different datasets and statistical methods have only been compared on the level of lists of differentially expressed genes. The goal of this study is to extend the comparison of different statistical methods and datasets to the level of affected pathways, and to compare the output of three recent group testing methods used for pathway analysis. Three public prostate cancer datasets were subjected to two distinct statistical analyses of differential expression, the Statistical Analysis of Microarrays (SAM; Tusher et al., 2001) and Mixed Model Analysis (MMA; Hsieh et al., 2003; Chu et al., 2002) . The six lists of genes obtained from these analyses were then subjected to ORA by Fisher's exact test (Draghici et al., 2003) . Normalized data of the three datasets were subjected to FCS by GSEA (Mootha et al., 2003; SweetCordero et al., 2005) and to global test (Goeman et al., 2004) .
METHODS

Public dataset collection and pre-processing
Data for this study were downloaded from public websites (Table 1) and were pre-processed by software packages included in the R-project (R Development Core Team, 2004; Ihaka and Gentleman, 1996) , Bioconductor (Gentleman et al., 2004) , and SAS Microarray 1.3 (SAS Institute Inc, 2004) . In all cases raw data were imported from CEL files. Normalization was carried out using the vsn (Huber et al., 2002) or MMN (Hsieh et al., 2003; Chu et al., 2002) algorithms with default parameters as implemented in the Bioconductor package vsn 1.5.0 or SAS Microarray 1.3, respectively. Data were two-base log-transformed. Vsn-normalized data were summarized by the medianpolish method (Tukey, 1977) . To calculate fold changes for vsn-normalized expression values the robust estimator expðhðx1Þ À hðx2ÞÞwas used (Huber et al., 2003) . For MMN data, summarization of probes was only necessary to calculate fold changes; this was done by calculating the median of each probe-set. Fold changes were then obtained by dividing the two averages.
Statistical analysis
For the identification of differentially expressed genes, SAM (Tusher et al., 2001) , as implemented in the siggenes 1.2.11 Bioconductor package, has been applied on vsn-normalized data and MMA (Hsieh et al., 2003; Chu et al., 2002) , as implemented in SAS Microarray 1.3, has been applied on MMN-normalized data. In all three datasets the same two classes, tumour versus normal, were compared. For multiple testing adjustment, the false discovery rate (FDR) was calculated, using the algorithm of Storey and Tibshirani (2003) for SAM and the algorithm of Benjamini and Hochberg (1995) for MMA. A threshold of 0.05 was used.
Group testing for pathway analysis
To identify pathways that are likely to be affected by differential expression three approaches were used; an ORA approach using Fisher's exact test as described by Draghici et al. (2003) , an FCS approach using a modified GSEA as described by Sweet-Cordero et al. (2005) and the global test approach as described by Goeman et al. (2004) and as implemented in the Bioconductor package globaltest 3.0.4. We used a total number of 227 pathway lists from which 132 were generated from the KEGG database (Kyoto Encyclopedia of Genes and Genomes, http://www.genome.ad.jp/ kegg/pathway.html) using the Bioconductor annotation package hgu95av2 1.8.4. A number of 95 pathways was generated manually (M. Kenzelmann).
2.4
Fisher's exact test (Draghici et al., 2003) We consider that there are N single-symbol-annotated genes on the microarray (replicates were averaged by calculating the mean), which are either significantly differentially expressed (S) or not (F), and either belong to a pre-defined pathway list (P) or not (NP), see Table 2 . If we pick randomly P genes, we would like to estimate the probability of having exactly a genes in S. The p-value of having a genes or fewer in S can be calculated by summing the probabilities of a random list of K genes having 1, 2, . . . , a genes in S:
This is a one-sided test in which the P values correspond to overrepresented lists of genes.
A review about similar current tools used for group testing on the level of Gene Ontology (GO) terms was given by Khatri and Draghici (2005) .
2.5 GSEA (Mootha et al., 2003; Sweet-Cordero et al., 2005) An earlier version of this approach, called also gene set enrichment analysis (GSEA), has previously been described by Lamb et al. (2003) and Mootha et al. (2003) . This procedure was extended by Sweet-Cordero et al., 2005 to address the case of multiple gene sets as well as multiple datasets. A refinement of the GSEA methodology with a broader applicability along several kinds of datasets has been given by Subramanian et al. (2005) . We use the basic GSEA procedure as described by Sweet-Cordero et al. (2005) , applying a phenotype permutation but no gene permutation. This is based on a maximum deviation statistic of two empirical distribution functions. First, the genes are ranked using the SNR (signal to noise ratio) with respect to their correlation with the phenotype of interest, in our case the comparison of tumour tissue versus normal tissue. The SNR is defined as
where, m C , m T , s C and s T are the mean expression values and the standard deviations of the control group C and the test group T, respectively. Second, an enrichment measure ES is calculated and assigned to each gene set as following. If L ¼ {g 1 , . . . , g N } are the ranked genes, the two empirical cumulative distribution functions are defined as
where G is the gene set that is to be tested, D the dataset under investigation, N H the number of genes in the gene set, Card½g j i 2 G the number of genes (cardinality) ranked above the ith gene that are in the gene set ('hits') and Card½g j i = 2G the number of genes (cardinality) ranked above the ith gene that are not in the gene set ('miss'). 
Group testing for pathway analysis
The enrichment score ES is the maximum difference between P hit and P miss , i.e.
ESðG‚ DÞ ¼ signðP hit ðG‚ D‚ iÞ À P miss ðG‚ D‚ iÞÞ · max i j P hit ðG‚ D‚ iÞ À P miss ðG‚ D‚ iÞ j : ð3Þ
Finally we calculate a nominal p-value to estimate the statistical significance of the enrichment score ES. This is done by permuting the class labels 999 times to produce reshuffled datasets D(p). Then we re-compute ranked lists by calculating the SNR of D(p). After that we calculate the enrichment score of each gene set for the new ranked lists, w p ¼ ESðG‚ DðpÞÞ. The nominal p-value of a gene set is determined by:
2.6 Global test (Goeman et al., 2004) This test investigates whether samples with similar clinical outcomes tend to have similar gene expression patterns. For a significant result, it suffices if many genes in the group are correlated with the outcome and not necessarily have similar expression patterns. The model used is
where Y i is the outcome of the sample i, h a link function (e.g. the logit function), a an intercept, x ij an element of the n · m data matrix of samples i and genes j, and b j the regression coefficient for gene
To test whether there is a predictive effect of the gene expressions on the clinical outcome, the null hypothesis that all regression coefficients are zero is tested, H 0 : (5) can be written as: 
RESULTS
Three public datasets (Table 1) were used to compare different statistical methods applied to these datasets on the level of apparently affected pathways. All three studies used the HGU95A (Welsh and Ernst) or HGU95Av2 (Singh) microarray platform from Affymetrix, and were consisting of the same two sample classes, normal prostate and prostate cancer. Each dataset was subjected to normalization by either vsn or MMN. Then, SAM was applied to the vsn-normalized data and MMA to the data normalized by MMN. Comparisons were made between prostate tumour and normal prostate tissue to detect genes that are significantly differentially expressed under these conditions. For multiple testing adjustment the FDR was calculated using the algorithm of Storey and Tibshirani for SAM and the algorithm of Benjamini and Hochberg for MMA. A threshold of 0.05 was used to assign differentially expressed genes. All differentially expressed genes with their significance values and fold-changes are to be found in Supplementary Table 1. The numbers of these genes and their overlap with those obtained from other statistical methods and datasets are shown by Venn diagrams (Fig. 1) . Figure 1a and b show the numbers of genes obtained by SAM or MMA applied to three datasets. The intersections of all three datasets contains 146 or 132 genes, respectively, which represent only 52 or 48 % of the smallest sets of significantly differentially expressed genes, which are from the data of Ernst. Comparing the overlaps between SAM or MMA genes for the three datasets (Fig. 1c-e) , the dataset of Welsh shows the highest rate of common genes of 84%, while the datasets of Singh and Ernst show rates of 63 or 65%, respectively. Finally, the common differentially expressed genes between SAM and MMA were compared with each other (Fig. 1f) . Here, the overall overlap of 76 genes represents just the 42% of the smallest set of significantly differentially expressed genes (dataset of Ernst).
Although the overlaps between different methods or between different datasets appear to be rather small, these are better compared by concordance plots that allow us to examine how big these discrepancies really are (Fig. 2, Supplementary Fig. 1 ). These plots show the numbers of common genes between significantly differentially expressed genes found by one analysis (y-axis) along the ranked list of all examined genes according to another analysis (x-axis). The area under the curve (AUC) determines the extent of concordance between the two analyses being compared. Hence, curves that are fast steeply increasing indicate a high concordance of the genes presented on the y-axis with the second analysis presented on the x-axis (e.g. Fig. 2i ), i.e. the genes on the x-axis get also high ranks in the second analysis. On the contrary, curves tending to the 45 diagonal line from the lower left corner to the upper right corner of the plot denote no similarity between the results of the two analyses (Fig. 2h) . The first six plots of both Figure 2 and Supplementary Figure 1 are comparisons between different analyses performed on the three data sets using the same statistical method (a-c: SAM and d-f: MMA). The dataset of Ernst shows the highest concordance of differentially expressed genes (large AUCs in Fig. 2c and f) . The Welsh and Singh datasets give concordance plots that are close to the 45 diagonal line, and this denotes that the differentially expressed genes of these data sets show a low concordance along ranked genes of other datasets (Fig. 2a, b, d and e) . In contrast, the concordance between the two statistical methods for same data sets (Fig. 2g-i , Supplementary  Fig. 1g-i ) was higher. SAM and MMA showed very good concordance rates for the dataset of Ernst, where all significantly differentially expressed genes found with one method were among the first 3000 top rated genes with the other method. For the dataset of Welsh, > 90% of the significantly differentially expressed genes found with one method were among the top 4000 ranked genes with the other method. The dataset of Singh showed, however, much lower concordance. This is presented by the short and not steeply ascending first phase of the concordance curve (Fig. 2h) .
As the next step, three approaches of group testing for pathway analysis have been applied. Fisher's exact test was applied to the six lists of significantly differentially expressed genes coming from three datasets and two statistical methods. GSEA and global test were applied to the three vsn-normalized datasets. For Fisher's exact test and GSEA, a threshold of 0.05 for the p-values was set to identify significantly regulated pathways. Because almost all examined pathways with the global test approach were assigned a p-value of < 0.05 we took the top 20 high-rated pathways for further investigation. their overlaps for each group testing method are presented in Table 3 . Figure 3 summarizes the occurrences of the significantly regulated pathways found with Fisher's exact test (Fig. 3a) , GSEA (Fig. 3b) , and global test (Fig. 3c) , respectively. A total number of six Fisher's exact test analyses have been applied on lists of significantly differentially expressed genes found with either SAM or MMA for the three public datasets of Welsh, Singh and Ernst, while for each GSEA and global test only three analyses have been applied directly to normalized data of these data sets, respectively. By Fisher's exact testing (Fig. 3a) one pathway, 'androgen and prostate cancer', was found to be significantly regulated in all six analyses. Two pathways, 'ribosome' and 'glutathione metabolism', were found to be significantly affected in five analyses, six pathways in four analyses, four pathways in three analyses, 17 pathways in two analyses and 17 pathways in only one analysis. GSEA (Fig. 3b) gave no affected pathways in more than one analysis. A total number of 23 pathways has been obtained by all analyses. By global testing eight pathways have been obtained by two analyses, while 44 pathways have been obtained by only one analysis.
Finally, the coincidence of affected pathways between the three group testing methods, Fisher's exact test, GSEA and global test is presented (Fig. 4) . For this purpose, pathways found to be significantly regulated in at least four of the six Fisher's exact test analyses and two of the three GSEA or global test analyses, were used. Three pathways, 'androgen and prostate cancer', 'pyrimidine metabolism' and 'nucleotide metabolism', were found to be affected by two group testing methods. A number of 11 pathways was found by only one method.
DISCUSSION
In this study we examined the discrepancies of different statistical methods and datasets on the level of affected pathways, and compared the output of three recent group testing methods used for pathway analysis. Data of three public prostate cancer datasets were pre-processed by vsn or MMN, and were then subjected to SAM or MMA, respectively. The FDR was calculated for multiple testing adjustment, and the threshold was set to 0.05 to assign differentially expressed genes. Three approaches of group testing for pathway analysis, Fisher's exact test, GSEA and global test, were applied to the three public datasets.
Comparing the overlaps of genes obtained from the two statistical methods and three datasets, we conclude that both different statistical methods and different datasets examining the same Glycosphingolipid metabolism (00600) Ribosome (03010) Fatty acid synthesis Glutathione metabolism (00480) Nucleotide metabolism
Valine, leucine and isoleucine degradation (00280) Fructose and mannose metabolism (00051) Androgen and prostate cancer Tyrosine metabolism (00350) Pentose phosphate pathway Urea cycle and metabolism of amino groups (00220) Glycine, serine and threonine metabolism (00260) Chondroitin / Heparan sulfate biosynthesis (00532) Arginine and proline metabolism (00330) Prion disease (05060) Glycogen metabolism (a)
(c) Fig. 3 . Coincidence of affected pathways found with (a) Fisher's exact test, (b) GSEA or (c) the global test from six different lists of genes. Each colour box designates that the corresponding pathway is significantly regulated in the corresponding list, coming from a specific dataset (Welsh, Singh or Ernst) and, for the case of Fisher's exact test, a specific statistical analysis (SAM or MMA). Significantly regulated pathways in 6 lists of genes are demonstrated in magenta, significantly regulated pathways in 5, 4, 3, 2 or 1 lists of genes are shown in red, blue, yellow or grey, respectively. The numbers in parenthesis following each pathway name denote the KEGG-ID (http://www.genome.ad. jp/kegg/pathway.html) for pathways coming from the KEGG pathway database. Pathways without number were complied and curated manually (M. Kenzelmann).
biological condition (in our case prostate cancer) lead to significant discrepancies. Different datasets showed higher dissimilarities in the obtained significantly differentially expressed genes than different statistical methods did. This observation was confirmed by investigating the concordance of a list of differentially expressed genes found by one analysis along the ranked list of all examined genes in another analysis. In general, genes obtained from the dataset of Ernst showed a higher concordance because of the smaller numbers of differentially expressed genes found in this dataset. These genes are expected to be the highly ranked among prostate cancer genes. Genes obtained from the dataset of Singh showed, in contrary, the worst concordance. The problem of having a small overlap between gene sets coming from different datasets has been also pointed out by Ein-Dor et al. (2005) . In this study one single dataset was analyzed by a single method and it was shown that the resulting set of genes is strongly influenced by the subset of patients used for gene selection. An explanation would be that there is a high number of differentially expressed genes, many of which are highly correlated. Which of them are chosen as the top-ranked genes is more or less arbitrary and depends on the analysis method or the set of samples from which the genes were inferred. One would expect, however, that these discrepancies are less pronounced when the genes are mapped to biological pathways.
Comparing the results of the three group testing methods (Fig. 3 ), Fisher's exact test followed by global test showed the highest overlap between affected pathways inferred from different datasets. 'Androgen and prostate cancer' was the pathway found to be apparently affected in all six Fisher's exact test analyses and in two global test analyses, and this supports the validity of these results. The GSEA gave no overlaps, which can be partly explained by the smaller numbers of apparently affected pathways gained by this method. However, most of the obtained pathways were also high rated pathways by the other two methods. As expected, results of group testing applied on different datasets were more discrepant than results of group testing applied on lists of differentially expressed genes obtained by different statistical methods (Fig. 3a) .
Examining the coincidence of affected pathways between the three group testing methods, Fisher's exact test, GSEA and global test (Fig. 4) , we observed that different methods gave mainly diverging results. Three pathways, 'androgen and prostate cancer', 'pyrimidine metabolism' and 'nucleotide metabolism', were found to be affected by two methods (Fisher's exact test and global test). GSEA gave, as mentioned above, no overlaps at all.
Many of the pathways found to be affected by differential expression are already known to be involved in prostate cancer pathogenesis. 'Androgen and prostate cancer' has a clear connection to prostate cancer as they were manually created from literature information on these diseases (M. Kenzelmann). Pathways from the group of nucleotide metabolism, amino acid metabolism, carbohydrate metabolism, as well as pathways like 'ribosome' are characteristic for fast proliferating tumour cells. 'Glutathione metabolism' plays an important role in defense against reactive oxygen species, xenobiotics and heavy metals (Mendoza-Cózatl et al., 2005) , while glutathione S-transferase pi (GSTP1) is a characteristically down-regulated marker gene in prostate cancer (Nakayama et al., 2004) . 'Gap junction proteins connexins' marks the increased cell communication in cancer for processes like apoptosis, differentiation and tissue homeostasis, and for activation of calcium and MAPK signalling pathways (http:// www.genome.ad.jp/kegg/pathway.html). 'Hypoxia' can be related to the increased intracellular redox state of prostate cancer cells, associated to the high oxidizing power of the fatty acid synthesis (FAS) pathway, that yields expression of hypoxia-regulated genes (Hochachka et al., 2002 ). An increased intracellular redox state yields also an increase in the expression of the intrinsic prion protein (PrPc), suggesting the possible participation of PrPc in antioxidative defense (Sauer et al., 1999) and explaining the high occurrence of 'prion disease' in our results.
Even a pathway as remote as 'Cholera-infection' yields some interesting results, as it contains genes of the adenylate cyclase signaling, phospholipase C and other factors that are also changed in tumour cells.
CONCLUSION
In conclusion, group testing applied to different datasets yields interesting common results, diminishing the large discrepancies observed in direct comparisons of lists of differentially expressed genes obtained not only from different datasets, but also by different statistical methods. Moreover, the multiple microarray analyses performed in this study result in discriminative pathway regulation signatures that are found and validated by different laboratories and microarray analysis methods. Pathways obtained by these analyses are likely to be more robust than those generated by a single analysis on a single dataset.
The three group testing methods used in this study differed in their results. Fisher's exact test showed the most consistent results with respect to the concordance between analyses on gene lists obtained by different methods from different datasets. Global test showed to a lesser extend consistent results between analyses applied to different datasets, while GSEA showed no overlaps between results coming from different datasets. All group testing Fig. 4 . Coincidence of affected pathways along the three different pathway analysis methods, Fisher's exact test, GSEA and global test. Pathways found to be affected in at least four of six Fisher's exact test analyses, or two of three GSEA or global test analyses, are presented. Yellow and grey boxes refer to significantly regulated pathways found with two or one pathway analysis methods, respectively. The numbers in parenthesis following each pathway name denote the KEGG-ID (http://www.genome.ad.jp/kegg/pathway).
